Development of Electrospun Membranes with Defined Polyethylene Collagen and Oxide Architectures Reinforced with Medium and High Intensity Statins

Authors: S. Jaramillo, Y. Montoya, W. Agudelo, J. Bustamante

Abstract:

Cardiovascular diseases (CVD) are related to affectations of the heart and blood vessels, within these are pathologies such as coronary or peripheral heart disease, caused by the narrowing of the vessel wall (atherosclerosis), which is related to the accumulation of Low-Density Lipoproteins (LDL) in the arterial walls that leads to a progressive reduction of the lumen of the vessel and alterations in blood perfusion. Currently, the main therapeutic strategy for this type of alteration is drug treatment with statins, which inhibit the enzyme 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMG-CoA reductase), responsible for modulating the rate of cholesterol production and other isoprenoids in the mevalonate pathway. This enzyme induces the expression of LDL receptors in the liver, increasing their number on the surface of liver cells, reducing the plasma concentration of cholesterol. On the other hand, when the blood vessel presents stenosis, a surgical procedure with vascular implants is indicated, which are used to restore circulation in the arterial or venous bed. Among the materials used for the development of vascular implants are Dacron® and Teflon®, which perform the function of re-waterproofing the circulatory circuit, but due to their low biocompatibility, they do not have the ability to promote remodeling and tissue regeneration processes. Based on this, the present research proposes the development of a hydrolyzed collagen and polyethylene oxide electrospun membrane reinforced with medium and high-intensity statins, so that in future research it can favor tissue remodeling processes from its microarchitecture.

Keywords: atherosclerosis, medium and high-intensity statins, microarchitecture, electrospun membrane

References:

[1] G. A. Roth et al., “Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019: Update from the GBD 2019 Study,” Journal of the American College of Cardiology, vol. 76, no. 25. Elsevier Inc., pp. 2982–3021, 22-Dec-2020.
[2] H. A. Strobel, E. I. Qendro, E. Alsberg, and M. W. Rolle, “Targeted delivery of bioactive molecules for vascular intervention and tissue engineering,” Front. Pharmacol., vol. 9, no. November, pp. 1–23, 2018.
[3] Y. M. Ju, J. S. Choi, A. Atala, J. J. Yoo, and S. J. Lee, “Bilayered scaffold for engineering cellularized blood vessels,” Biomaterials, vol. 31, no. 15, pp. 4313–4321, 2010.
[4] Z. Tan, H. Wang, X. Gao, T. Liu, and Y. Tan, “Composite vascular grafts with high cell infiltration by co-electrospinning,” Mater. Sci. Eng. C, vol. 67, pp. 369–377, 2016.
[5] W. Zeng, Y. Li, Y. Wang, and Y. Cao, “Tissue engineering of blood vessels,” in Encyclopedia of Tissue Engineering and Regenerative Medicine, vol. 1–3, Elsevier Inc., 2019, pp. 413–424.
[6] M. Kuk, N. C. Ward, and G. Dwivedi, “Extrinsic and Intrinsic Responses in the Development and Progression of Atherosclerosis,” Heart Lung and Circulation. Elsevier Ltd, 16-Jan-2021.
[7] S. Barquera et al., “Global Overview of the Epidemiology of Atherosclerotic Cardiovascular Disease,” Arch. Med. Res., vol. 46, no. 5, pp. 328–338, Jul. 2015.
[8] R. Pahwa and I. Jialal, “Atherosclerosis,” Diet, Exerc. Chronic Dis. Biol. Basis Prev., pp. 133–210, Aug. 2020.
[9] I. Pinal-Fernandez, M. Casal-Dominguez, and A. L. Mammen, “Statins: pros and cons,” Medicina Clinica, vol. 150, no. 10. Ediciones Doyma, S. L., pp. 398–402, 23-May-2018.
[10] S. Mennickent C, M. Bravo D., C. Calvo M, and M. Avello L, “Efectos pleiotrópicos de las estatinas,” Rev. Med. Chil., vol. 136, no. 6, pp. 775–782, Jun. 2008.
[11] B. Mihaylova et al., “The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: Meta-analysis of individual data from 27 randomised trials,” Lancet, vol. 380, no. 9841, pp. 581–590, Aug. 2012.
[12] E. Biros, J. E. Reznik, and C. S. Moran, “Role of inflammatory cytokines in genesis and treatment of atherosclerosis,” Trends Cardiovasc. Med., Feb. 2021.
[13] Q. Langouet et al., “Incidence, predictors, impact, and treatment of vascular complications after transcatheter aortic valve implantation in a modern prospective cohort under real conditions,” J. Vasc. Surg., vol. 72, no. 6, pp. 2120-2129.e2, Dec. 2020.
[14] Q. Zhang et al., “Heparinization and hybridization of electrospun tubular graft for improved endothelialization and anticoagulation,” Mater. Sci. Eng. C, vol. 122, no. January, p. 111861, 2021.
[15] I. Cicha, R. Singh, C. Garlichs, and C. Alexiou, “Nano-biomaterials for cardiovascular applications: Clinical perspective,” J. Control. Release, vol. 229, pp. 23–36, 2016.
[16] A. Subramaniam and S. Sethuraman, “Biomedical Applications of Nondegradable Polymers,” in Natural and Synthetic Biomedical Polymers, Elsevier Inc., 2014, pp. 301–308.
[17] Y. M. Ju et al., “Electrospun vascular scaffold for cellularized small diameter blood vessels: A preclinical large animal study,” Acta Biomater., vol. 59, pp. 58–67, 2017.
[18] D. M. García Cruz, “Materiales macroporosos biodegradables basados en quitosano para la ingeniería tisular,” pp. 1–223, 2008.
[19] S. N. Hanumantharao and S. Rao, “Multi-functional electrospun nanofibers from polymer blends for scaffold tissue engineering,” Fibers, vol. 7, no. 7, pp. 1–35, 2019.
[20] D. A. Florea, V. Grumezescu, A. M. Grumezescu, and E. Andronescu, “Clinical applications of bioactive materials,” in Materials for Biomedical Engineering: Bioactive Materials, Properties, and Applications, V. Grumezescu and A. M. Grumezescu, Eds. Elsevier, 2019, pp. 527–543.
[21] X. Zhao, “Introduction to bioactive materials in medicine,” in Bioactive Materials in Medicine: Design and Applications, X. Zhao, J.M. Courtney, and H. Qian, Eds. Elsevier Inc., 2011, pp. 1–13.
[22] M. G. Yeo and G. H. Kim, “Fabrication of cell-laden electrospun hybrid scaffolds of alginate-based bioink and PCL microstructures for tissue regeneration,” Chem. Eng. J., vol. 275, pp. 27–35, 2015.
[23] H. Ahn et al., “Engineered small diameter vascular grafts by combining cell sheet engineering and electrospinning technology,” Acta Biomater., vol. 16, no. 1, pp. 14–22, 2015.
[24] R. Dorati et al., “Electrospun tubular vascular grafts to replace damaged peripheral arteries: A preliminary formulation study,” Int. J. Pharm., vol. 596, p. 120198, Feb. 2021.
[25] D. Hao et al., “Rapid endothelialization of small diameter vascular grafts by a bioactive integrin-binding ligand specifically targeting endothelial progenitor cells and endothelial cells,” Acta Biomater., vol. 108, pp. 178–193, 2020.
[26] M. A. Nazeer, E. Yilgor, and I. Yilgor, “Electrospun polycaprolactone/silk fibroin nanofibrous bioactive scaffolds for tissue engineering applications,” Polymer (Guildf)., vol. 168, pp. 86–94, 2019.
[27] J. Dulnik, D. Kołbuk, P. Denis, and P. Sajkiewicz, “The effect of a solvent on cellular response to PCL/gelatin and PCL/collagen electrospun nanofibres,” Eur. Polym. J., vol. 104, pp. 147–156, Jul. 2018.
[28] X. Zhou et al., “Ca ions chelation, collagen I incorporation and 3D bionic PLGA/PCL electrospun architecture to enhance osteogenic differentiation,” Mater. Des., vol. 198, p. 109300, Jan. 2021.
[29] O. Pereao et al., “Chitosan/PEO nanofibers electrospun on metallized track-etched membranes: fabrication and characterization,” Mater. Today Chem., vol. 20, p. 100416, Jun. 2021.
[30] M. Zarei, A. Samimi, M. Khorram, M. M. Abdi, and S. I. Golestaneh, “Fabrication and characterization of conductive polypyrrole/chitosan/collagen electrospun nanofiber scaffold for tissue engineering application,” Int. J. Biol. Macromol., vol. 168, pp. 175–186, Jan. 2021.
[31] J. G. Fernandes et al., “PHB-PEO electrospun fiber membranes containing chlorhexidine for drug delivery applications,” Polym. Test., vol. 34, pp. 64–71, Apr. 2014.
[32] C. Stani, L. Vaccari, E. Mitri, and G. Birarda, “FTIR investigation of the secondary structure of type I collagen: New insight into the amide III band,” Spectrochim. Acta Part A Mol. Biomol. Spectrosc., vol. 229, p. 118006, Mar. 2020.
[33] Y. Zhang, Z. Chen, X. Liu, J. Shi, H. Chen, and Y. Gong, “SEM, FTIR and DSC Investigation of Collagen Hydrolysate Treated Degraded Leather,” J. Cult. Herit., vol. 48, pp. 205–210, Mar. 2021.
[34] J. Spěváček, R. Konefał, J. Dybal, E. Čadová, and J. Kovářová, “Thermoresponsive behavior of block copolymers of PEO and PNIPAm with different architecture in aqueous solutions: A study by NMR, FTIR,
[35] V. M. Sonje et al., “Atorvastatin Calcium,” Profiles Drug Subst. Excipients Relat. Methodol., vol. 35, pp. 1–70, Jan. 2010.
[36] P. Mounka, Y. Padavathi, A. Anjali, and N. P. REDDY, “Quantitative estimation of Atorvastatin calcium in bulk and tablet dosage forms using FTIR spectroscopy,” Int. J. Pharma Bio Sci., vol. 9, no. 2, May 2018.